Clinical trials: Plague
Asthma
Asthma and Pest Control Study: Demonstrating Return-on-Investment for In-Home Pest Control for Children With Persistent Asthma
The New York City Department of Health and Mental Hygiene and Montefiore Medical Center, with the Fund for Public Health of New York (FPHNY), DOHMH's fiscal agent, are partnering on a study to evaluate the feasibility, health…
- Trial name
- NCT02700542
- Testing
- Integrated Pest Management
- Where
- 2 sites in United States
- Volunteers
- 384 people, healthy volunteers welcome
- Sponsor
- New York City Department of Health and Mental Hygiene
Plague
Immunogenicity and Safety of Subunit Plague Vaccine
Plague is a potentially fatal infection in humans caused by the bacterium Yersinia pestis. Pneumonic plague is typically diagnosed in humans with high mortality.
- Trial name
- NCT02596308
- Testing
- Plague vaccine
- Where
- China
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
Healthy
The Effect of Brushing With Fluoride Toothpaste on Dental Plague Control for Elementary School Students
The purpose of this study is to evaluate the effect of correct tooth cleaning and use of fluoride toothpaste after school lunch and before going to bed on primary school children's plaque reduction and tooth cleaning skills.
- Trial name
- NCT06116825
- Testing
- 1450ppm Fluoride toothpaste, 1000Pppm Fluoride toothpaste
- Where
- Taiwan
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
Plague
One Year Study to Evaluate Three Different Adjuvanted Doses of the Recombinant Plague Vaccine (rF1 and rV Antigens)
One hundred and five subjects will be recruited into three groups. Each subject will receive two doses of recombinant plague vaccine at one of three dose levels (rF1 and rV recombinant antigen proteins).
- Trial name
- NCT00246467
- Testing
- Alhydrogel, rF1 and rV protein antigens
- Where
- 10 sites in United States, United Kingdom
- Volunteers
- 123 people, healthy volunteers welcome
- Sponsor
- PharmAthene UK Limited
Plague
Dose Escalation Trial of a Plague Vaccine, Flagellin/F1/V, in Healthy Adult Volunteers
Plague is an infectious disease of animals and humans caused by bacteria, Yersinia pestis. Modern antibiotics are effective against plague, but if an infected person is not treated promptly the disease is likely to cause illness…
- Trial name
- NCT01381744
- Testing
- Flagellin/F1/V
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Plague Vaccine
Randomized Single-Blinded Study to Evaluate Safety and Immunogenicity of Recombinant Plague Vaccine With and Without Adjuvant
Multicenter, randomized, single-blinded comparison of two formulations of the rF1V vaccine at a single dosage of 80 µg and two 3-dose schedules in 400 healthy, adult volunteers in four parallel cohorts.
- Trial name
- NCT01122784
- Testing
- rF1V vaccine (with Adjuvant), rF1V vaccine (without Adjuvant)
- Where
- 11 sites in United States
- Volunteers
- 402 people, healthy volunteers welcome
- Sponsor
- DynPort Vaccine Company LLC, A GDIT Company
Children, Only, Risk Reduction
Reducing Pesticide Exposures in Child Care Centers
A randomized control study was conducted to reduce the exposure to pesticides in child care centers. A 7-month child care health consultant-led integrated pest management (IPM) intervention was conducted in 85 child care centers…
- Conditions
- Children, Only, Risk Reduction, Environmental Exposure
- Trial name
- HCES (NCT03319927)
- Testing
- Changes in pesticide exposure, IPM Practices, Educational Workshops
- Where
- United States
- Volunteers
- 987 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Plague
Immunogenicity and Safety of Subunit Vaccine of Plague Vaccine With Two Immunization Regimens
Plague is a potentially fatal infection in humans caused by the bacterium Yersinia pestis. Pneumonic plague is typically diagnosed in humans with high mortality.
- Trial name
- NCT05330624
- Testing
- plague vaccine(F1+rV)
- Where
- China
- Volunteers
- 720 people, healthy volunteers welcome
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
Pneumonic Plague, Preventive Therapy
Safety, Tolerability & Immunogenicity of the Recombinant Plague Vaccine rF1V
The purpose of this study is to evaluate the safety and tolerability of a two-dose schedule of the recombinant plague vaccine rF1V in healthy volunteers when given as an intramuscular (IM) injection at four ascending dose-levels.
- Trial name
- NCT00097396
- Testing
- rF1V vaccine
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- DynPort Vaccine Company LLC, A GDIT Company
Prevention of Pneumonic Plague Resulting From Aerosol Exposure to Yersinia Pestis
Immunogenicity, Safety, and Tolerability of rF1V-1018 Vaccine in Adults 18 to 55 Years of Age
This study will evaluate the immunogenicity, safety, and tolerability of rF1V-1018 vaccine
- Trial name
- NCT07207408
- Testing
- rF1V-1018
- Where
- 4 sites in United States
- Volunteers
- 148 people, healthy volunteers welcome
- Sponsor
- Dynavax Technologies Corporation
Plaque Psoriasis, Psoriatic Arthritis
Modifying PEST for Psoriatic Arthritis Screening
The purpose of this study is to assess the impact of adding two questions and pictures to the validated PEST on the potential diagnosis of PsA in participants with moderate-to-severe plaque PsO in Canada.
- Trial name
- ScreenX (NCT06382051)
- Testing
- PEST Screening group
- Where
- 30 sites in Canada
- Volunteers
- 502 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Pre-exposure Prophylaxis Against Pneumonic Plague in Healthy Adults
Ph1, Randomized, Double-Blind and Controlled, Dose Escalation and Expansion Study to Assess the Safety and Pharmacokinetics of JST-010 in Healthy Adults
The goal of this clinical trial is to learn if a single dose of the study drug, JST-010, is safe and tolerable when administered by injection into the arm or thigh muscle of healthy men and women aged 18 to 55.
- Trial name
- NCT06943378
- Testing
- Monoclonal antibody JST-010
- Where
- United States
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- Just-Evotec Biologics
Major Depressive Disorder
Pathophysiology of Neurodegeneration in Late-life Depression (AV45+THK)
Late-life depression has been frequently associated with cognitive impairment. Several meta-analyses consistently suggested that a history of depression approximately doubles an individual's risk for developing dementia later in…
- Trial name
- NCT03430869
- Testing
- F-18 AV-45, F-18-THK-5351
- Where
- Taiwan
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- Chang Gung Memorial Hospital
Plague, Pneumonic, Plague
Trial of the Immunogenicity, Safety, and Tolerability of rF1V Vaccine With CpG 1018® Adjuvant Compared With rF1V Vaccine in Adults 18 to 55 Years of Age
Phase 2, Randomized, Active-Controlled, Observer-Blinded, Multicenter Trial of the Immunogenicity, Safety, and Tolerability of rF1V Vaccine with CpG 1018® Adjuvant Compared with rF1V Vaccine in Adults 18 to 55 Years of Age
- Conditions
- Plague, Pneumonic, Plague, Vaccine-Preventable Diseases
- Trial name
- NCT05506969
- Testing
- rF1V-1018, rF1V vaccine
- Where
- 6 sites in United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Dynavax Technologies Corporation
Healthy Volunteers
Title: Recombinant Plague Vaccine rF1V in Healthy Volunteers
This Phase 2(a) clinical trial is designed as a dose-blinded, block-randomized, multi-center study to select a dosage and schedule of rF1V vaccine for further studies based on the immune response up to Day 210.
- Trial name
- NCT00332956
- Testing
- rFIV vaccine, rF1V vaccine, rF1V vaccine 160 mcg given on Study Days 0, 56, 182
- Where
- 9 sites in United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- DynPort Vaccine Company LLC, A GDIT Company